secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000528
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro STRO-002 Phase 1 shows 43.8% ORR in FolRα-selected ovarian cancer; registrational study Q2 2023
--------------------------------------------------------------------------------

- STRO-002 (luvelta) Phase 1 dose-expansion: 43.8% ORR, median DOR 5.4 mo, median PFS 6.6 mo at 5.2 mg/kg in FolRα-selected (TPS>25%) patients.
- FolRα-selected population (~80% of advanced ovarian cancer) drove benefit; unselected patients had 11.1% ORR.
- Prophylactic pegfilgrastim reduced Grade 3+ neutropenia 85% (66.7% to 10%) and dose delays 60.6% at cycle 2.
- Phase 2/3 registration-directed study REFRaME to start Q2 2023; potential accelerated approval based on ORR endpoint.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023000528/0000950170-23-000528-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017023000528/stro-20230109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000528

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer